Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
poloxamer 188 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| poloxamer 188 | DRUG | - |
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- * Sickle cell disease confirmed by electrophoresis or high pressure liquid chromatography * At least one prior documented painful crisis episode but no greater than 10 crises per year for the last two years * Sudden onset of acute pain lasting 4...
Poloxamer 188 is an investigational small molecule being developed for the treatment of sickle cell anemia. It is intended to address vaso-occlusive crises, which are painful episodes caused by blocked blood flow. The drug is currently in Phase 3 clinical development.
Poloxamer 188 is a small molecule that targets sickle cell anemia. It is designed to improve blood flow and reduce vaso-occlusive crises, though the specific molecular target has not been disclosed. The drug is being evaluated for its ability to alleviate symptoms associated with the condition.
Poloxamer 188 is being developed by Savara, Inc., a biopharmaceutical company. Savara is listed on the stock exchange under the ticker symbol SVRA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with sickle cell anemia.
Poloxamer 188 is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the results will inform potential regulatory submissions.
Poloxamer 188 has one completed Phase 3 clinical trial, identified as NCT00004408. This randomized, double-blind study enrolled 300 patients with sickle cell anemia to evaluate the drug for vaso-occlusive crises. The trial has been completed, and no active trials are currently listed.
Poloxamer 188 is not known by any alternative names. It is a distinct investigational compound being developed by Savara, Inc. for sickle cell anemia. No other names have been associated with this drug in clinical development.